ACE and hydrops fetalis: In the clinical phase III trial, ARNI demonstrated a lower rate of hospitalization for HF or death from cardiovascular causes than enalapril, an angiotensin-converting enzyme inhibitor (ACEI), in patients with HF with reduced ejection fraction (HFrEF) (≤ 40%) [4].